liraglutide / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 112 Diseases   125 Trials   125 Trials   6082 News 


«12345678910111213...6465»
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk
    Biomarker, Retrospective data, Journal:  Predictive factors of response to liraglutide in patients with type 2 diabetes mellitus and metabolic syndrome. (Pubmed Central) -  Oct 21, 2024   
    The area under the curve of the ROC for the three predictors of liraglutide response after 6 months of treatment was 0.851 (95% confidence interval: 0.793 - 0.910). The baseline HbA1c, baseline BMI, and duration of T2DM were shown to be predictive factors of glycemic and weight improvements in patients with T2DM and MS treated with liraglutide, and had good predictive power.
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk
    Journal:  The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy. (Pubmed Central) -  Oct 19, 2024   
    This large community-based cohort study investigates the impact of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), specifically Liraglutide and Semaglutide, on the risk of developing psychiatric conditions such as depression, anxiety, and suicidal behaviors in patients with obesity...Notably, patients on GLP-1 RAs exhibited a 195% higher risk of major depression, a 108% increased risk for anxiety, and a 106% elevated risk for suicidal behavior. These findings underscore the critical need for physicians to thoroughly assess patient history before prescribing GLP-1 RAs and highlight the urgent requirement for further prospective clinical trials to fully understand the implications of GLP-1 RA use on mental health in the obese patient population.
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk
    Observational data, Retrospective data, Journal, Real-world evidence, Surgery, Bariatric surgery, Real-world:  Use of liraglutide after bariatric surgery: a 36-month follow-up in a real-world setting in Chile. (Pubmed Central) -  Oct 18, 2024   
    Liraglutide was well tolerated, but cost barriers led to several patients interrupting its use. Liraglutide is an effective and safe treatment for weight reduction after bariatric surgery in patients receiving routine clinical care in Chile.
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen, Xenical (orlistat) / Roche, GSK
    Journal:  Long-Term Assessment of Weight Loss Medications in a Veteran Population. (Pubmed Central) -  Oct 16, 2024   
    However, there were no statistically significant differences among the medications. Patients did not receive uniformly consistent follow-up care, suggesting the need for more standardized processes that could lead to better weight loss outcomes.
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk, Mounjaro (tirzepatide) / Eli Lilly
    Journal:  Estimating the lives that could be saved by expanded access to weight-loss drugs. (Pubmed Central) -  Oct 15, 2024   
    Specifically, we project that with expanded access, over 42,000 deaths could be averted annually, including more than 11,000 deaths among people with type 2 diabetes. These findings underscore the urgent need to address barriers to access and highlight the transformative public health impact that could be achieved by expanding access to these novel treatments.
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk
    THE IMPACT OF LIRAGLUTIDE ON PATIENTS WITH METABOLIC DYSFUNCTION ASSOCIATED FATTY LIVER DISEASE () -  Oct 15, 2024 - Abstract #AASLD2024AASLD_2318;    
    These findings suggest that liraglutide may be a beneficial therapeutic option for managing MASLD, particularly in patients with obesity and metabolic syndrome. Further long-term studies are needed to confirm these benefits and assess the effects on liver-related morbidity and mortality.
  • ||||||||||  EVALUATION OF MASH DRUG EFFICACY USING LIVER ORGANOIDS BASED ON DRUG TARGET PATHWAYS () -  Oct 15, 2024 - Abstract #AASLD2024AASLD_2302;    
    Then, we administered the following drugs alone or in combination: Resmetirom (10 ?M), Lanifibranor (80 ?M), Firsocostat (20 ?M) and Liraglutide (20 ?M). Although accurately reproducing the lipid metabolism of actual patients is difficult, the organoid model was shown to be more appropriate for evaluating drug efficacy than the existing in vitro 2D cell models.
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk, Byetta (exenatide) / AstraZeneca, Trulicity (dulaglutide) / Eli Lilly
    MAINTENANCE THERAPY WITH GLP-1 RECEPTOR AGONISTS DOES NOT IMPACT THE? CLEARANCE OF ORALLY ADMINISTERED ISOTOPES OF UNCONJUGATED CHOLATE () -  Oct 15, 2024 - Abstract #AASLD2024AASLD_1487;    
    This analysis demonstrates that there is little to no impact of maintenance GLP-1 RAs on the clearance of an orally-administered d4-CA liquid solution. However, because the effect of GLP-1 RAs on gastric emptying may vary with type of GLP-1 RA and duration of GLP-1 RA treatment, and some may have dual (GIP) or triple (GIP, amylin) effects, we advise holding GLP-1 RAs (and other drugs that slow gastric emptying) for 7 days prior to administering the HepQuant tests.
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk
    Preclinical, Journal:  Renoprotective effect of liraglutide on diabetic nephropathy by modulation of Kr (Pubmed Central) -  Oct 15, 2024   
    Liraglutide can slow the progression of DN by modulating KLF5-related lysophosphatidic acid axis. Thus, liraglutide may be an effective treatment for preventing or mitigating diabetes-related kidney damage.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Semaglutide-Induced Severe AKI Requiring Hemodialysis () -  Oct 12, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_4964;    
    Nephrotoxic medications were held and she received DDAVP for bleeding at an IV site...A post hoc analysis of the STEP 1, 2, and 3 trials revealed that semaglutide did not worsen renal outcomes regardless of patients' baseline renal function.1 A meta-analysis of FDA data indicated liraglutide had the highest risk of AKI, followed by semaglutide.2 Our patient developed AKI with uremia without existing renal disease. Extensive workup ruled out other causes such as immunologic, obstruction, etc., suggesting the presentation was due to semaglutide..
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk
    Glucagon-Like Peptide 1 Receptor Agonist Attenuates Cardiovascular Injury Caused by Renal Fibrosis (Room 5, Convention Center) -  Oct 12, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_4607;    
    We demonstrated that GLP-1RA attenuated the damage to the heart caused by CKD to some degree. This cardioprotective effect highlights the potential therapeutic benefits of GLP-1RA in reducing secondary heart damage caused by CKD in the context of cardiorenal syndromes.
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk, Mounjaro (tirzepatide) / Eli Lilly
    Journal:  Polycystic ovary syndrome and type 1 diabetes - the current state of knowledge. (Pubmed Central) -  Oct 8, 2024   
    In obese patients with T1DM and PCOS glucagon-like peptide-1 receptor agonists (GLP-1 Ras) (liraglutide, semaglutide) and dual glucose-dependent insulinotropic polypeptides (GIP)/GLP-1 RAs (tirzepatide) are regarded as a safe approach...The gut microbiome is also considered as a critical modulator of the predisposition to PCOS and T1DM and may be the future goal of the treatment. The proper treatment of PCOS will translate into a reduction in the severity of typical symptoms and also into the improvement in the metabolic control of diabetes and the patients' quality of life.
  • ||||||||||  liraglutide subcutaneous prolonged-release (NEX-22) / Nanexa AB
    Enrollment closed:  Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D (clinicaltrials.gov) -  Oct 2, 2024   
    P1,  N=9, Active, not recruiting, 
    Integrating GLP-1-RAs into clinical practice can enhance patient outcomes and reduce the community burden of cardiometabolic disease. Recruiting --> Active, not recruiting
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk
    Journal:  Effect of preoperative liraglutide 3.0 (Pubmed Central) -  Sep 30, 2024   
    Liraglutide has introduced a new way to treat obesity, improving weight loss and comorbidities. Gastrointestinal disorders, such as subclinical pancreatitis, associated with GLP-1 analogue could explain the elevated incidence of intraoperative adhesions during bariatric surgery.
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk
    Preclinical, Journal, Metabolomic study, Machine learning:  Machine Learning-Based Plasma Metabolomics in Liraglutide-Treated Type 2 Diabetes Mellitus Patients and Diet-Induced Obese Mice. (Pubmed Central) -  Sep 27, 2024   
    Through the cross-evaluation of machine learning models, we found that liraglutide promotes metabolic shifts and interspecies correlations in these shifts between DIO mice and patients with T2DM. Our comparative analysis helped identify metabolic correlations influenced by liraglutide between humans and rodents and may guide future therapeutic strategies for T2DM and obesity.
  • ||||||||||  Review, Journal:  Emerging drugs for the treatment of short bowel syndrome. (Pubmed Central) -  Sep 26, 2024   
    Our comparative analysis helped identify metabolic correlations influenced by liraglutide between humans and rodents and may guide future therapeutic strategies for T2DM and obesity. Clinical trials and real-world experience demonstrated that Teduglutide
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk
    Trial completion date, Trial primary completion date:  Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia (clinicaltrials.gov) -  Sep 26, 2024   
    P2/3,  N=0, Withdrawn, 
    A single-center, prospective study was undertaken to evaluate the changes in the plasma proteins after liraglutide 3 mg therapy in twenty patients (M/F: 7/13) with obesity (mean BMI 40.65 Trial completion date: Nov 2024 --> Nov 2026 | Trial primary completion date: Nov 2022 --> Nov 2025
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk
    Review, Journal:  Liraglutide innovations: a comprehensive review of patents (2014-2024). (Pubmed Central) -  Sep 24, 2024   
    Liraglutide is one of the potent drugs of this class having similar effects as biological GLP-1. This review includes clinical trials and patents related to the pharmaceutical formulation, synthesis and biological action of liraglutide.
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk
    Journal:  Utilization of antiobesity medications within the Military Health System. (Pubmed Central) -  Sep 24, 2024   
    This review includes clinical trials and patents related to the pharmaceutical formulation, synthesis and biological action of liraglutide. Comparable with the US private sector, the MHS significantly underutilizes AOMs, including among active-duty service members, despite coverage of AOMs since 2018.
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk
    Clinical, Journal:  Liraglutide and Colesevelam Changes Serum and Fecal Bile Acid Levels in a Randomized Trial with Patients with Bile Acid Diarrhea. (Pubmed Central) -  Sep 23, 2024   
    Comparable with the US private sector, the MHS significantly underutilizes AOMs, including among active-duty service members, despite coverage of AOMs since 2018. Colesevelam and liraglutide exhibit distinct effects on serum and fecal bile acid concentrations with colesevelam reducing serum concentrations of secondary bile acids and promoting fecal bile acid excretion while liraglutide enhances serum concentrations of unconjugated bile acids, potentially through deceleration of small intestinal transit time allowing more time for passive absorption of bile acids.
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk
    Liraglutide-Mediated Renoprotection in Type 1 Diabetes: Modulating M1/M2 Macrophage Balance via NOX/TRP Cross-Talk (Exhibit Hall, Convention Center) -  Sep 23, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_2548;    
    Targeting the MAP4K1-cGAS-STING axis could be a viable strategy for developing new treatments for chronic kidney disease (CKD), highlighting the therapeutic potential of GLP1R agonists in renal protection. This is the first study to show a reno-protective effect of liraglutide in T1DM manifested by a shift in macrophage polarization from M1 inflammatory to M2 anti-inflammatory phenotype by modulating NOX-TRP crosstalk.